54,015 Shares in Solventum Co. (NYSE:SOLV) Acquired by Mubadala Investment Co PJSC

Mubadala Investment Co PJSC purchased a new stake in Solventum Co. (NYSE:SOLV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 54,015 shares of the company's stock, valued at approximately $3,568,000. Solventum accounts for about 0.0% of Mubadala Investment Co PJSC's investment portfolio, making the stock its 27th largest holding.

A number of other institutional investors also recently modified their holdings of the business. Norges Bank bought a new position in shares of Solventum in the 4th quarter worth $203,740,000. Boston Partners purchased a new stake in Solventum during the fourth quarter valued at about $110,378,000. Independent Franchise Partners LLP lifted its stake in Solventum by 105.0% during the fourth quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company's stock worth $105,904,000 after purchasing an additional 821,272 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Solventum by 41.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,193,361 shares of the company's stock worth $78,833,000 after purchasing an additional 347,669 shares in the last quarter. Finally, Candlestick Capital Management LP grew its position in Solventum by 67.7% during the fourth quarter. Candlestick Capital Management LP now owns 802,606 shares of the company's stock valued at $53,020,000 after acquiring an additional 323,920 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a report on Monday, March 3rd. Piper Sandler reduced their price target on Solventum from $80.00 to $78.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Wells Fargo & Company increased their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Finally, Mizuho raised their target price on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $79.00.

Solventum Stock Up 1.6%

Shares of SOLV traded up $1.14 on Friday, hitting $74.08. 824,004 shares of the stock traded hands, compared to its average volume of 1,248,613. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The company has a market capitalization of $12.82 billion and a PE ratio of 34.30. The business has a 50 day simple moving average of $69.79 and a 200 day simple moving average of $71.27. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.15. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. The business's revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.08 earnings per share. As a group, equities analysts forecast that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.